Yes, immune thrombocytopenia (ITP) is classified as an organ-specific autoimmune disease. The immune system mistakenly targets and destroys the body’s own platelets, the tiny blood cells responsible for clotting. This results in abnormally low platelet counts, typically below 100,000 per microliter of blood (normal range is 150,000 to 400,000), which can lead to easy bruising and, in severe cases, dangerous bleeding.
How the Immune System Attacks Platelets
Like other autoimmune diseases, ITP begins with a breakdown in self-tolerance, the system that normally prevents immune cells from attacking the body’s own tissues. When this fails, the immune system treats platelets as foreign invaders and mounts a response against them.
The attack happens through multiple pathways. The most well-known, recognized since the 1950s, involves autoantibodies that latch onto specific proteins on the platelet surface. But the immune assault goes beyond antibodies. T cells, another branch of the immune system, directly kill platelets and also attack megakaryocytes, the large bone marrow cells that produce platelets in the first place. This dual problem means ITP causes both accelerated platelet destruction and reduced platelet production.
The spleen plays a central role on both sides of this process. Its white pulp manufactures the autoantibodies, while its red pulp acts as the primary site where antibody-coated platelets are engulfed and destroyed by immune cells called macrophages. Platelets pass slowly through the spleen’s narrow channels, giving macrophages ample time to grab anything marked by antibodies. This is why surgical removal of the spleen restores normal platelet counts in most patients who need that option.
Primary ITP vs. Secondary ITP
When ITP develops on its own with no identifiable trigger, it’s called primary ITP. This is the most common form. Secondary ITP, on the other hand, occurs alongside or as a result of another condition. Common triggers include infections with HIV, hepatitis, or H. pylori (the bacterium behind stomach ulcers). People with other autoimmune diseases like lupus or rheumatoid arthritis also face a higher risk. In secondary ITP, treating the underlying condition sometimes resolves the low platelet count.
Who Gets ITP
ITP affects both children and adults, though the pattern differs between the two groups. The estimated incidence in children ranges from about 1.9 to 6.4 cases per 100,000 per year, while adults develop ITP at a rate of roughly 3.3 per 100,000 per year. In children, ITP often appears suddenly after a viral infection and tends to resolve on its own. One large study of nearly 500 children with severe ITP found that 73% went into remission within three months and another 8% recovered between six and twelve months. About 21% developed chronic ITP lasting beyond a year.
Adults are more likely to develop the chronic form from the start, and spontaneous remission is less common.
What ITP Feels Like
The symptoms of ITP reflect what happens when you don’t have enough platelets to form clots properly. The most visible sign is “dry purpura,” which includes spontaneous bruises and petechiae (tiny reddish-purple dots on the skin caused by bleeding under the surface). “Wet purpura” involves bleeding from mucous membranes, often visible as blood blisters inside the mouth.
How much you bleed depends heavily on your platelet count. Severe bleeding is distinctly uncommon when platelet counts stay above 30,000 per microliter. Major bleeding, including gastrointestinal or intracranial hemorrhage, typically only occurs when counts drop below 10,000. Many people with mild ITP have no symptoms at all and discover the condition through routine blood work.
How ITP Is Treated
Not everyone with ITP needs treatment. The decision depends on platelet count, bleeding symptoms, and how the condition affects daily life. When treatment is necessary, the first step for both adults and children is a short course of corticosteroids, which suppress the immune system’s attack on platelets. The American Society of Hematology recommends keeping steroid courses to six weeks or shorter in adults and seven days or shorter in children, since prolonged steroid use carries significant side effects.
For people whose ITP doesn’t respond to steroids or returns after treatment ends, several second-line options exist. One important class of medications works by stimulating the bone marrow to produce more platelets, essentially compensating for the increased destruction rather than stopping the immune attack itself. These drugs bind to receptors on megakaryocytes and ramp up platelet production. Some are taken as daily pills, others as weekly injections.
Spleen removal remains an option for chronic ITP that resists other treatments. Because the spleen is the primary site of both autoantibody production and platelet destruction, removing it addresses the problem at its source. Other therapies target specific immune cells to interrupt the autoimmune cycle at different points.
How ITP Compares to Other Autoimmune Diseases
ITP shares its core mechanism with many autoimmune conditions: the immune system loses the ability to distinguish self from non-self and launches an attack on healthy tissue. What makes ITP “organ-specific” is that this attack is narrowly focused on platelets rather than affecting multiple organs or tissues the way lupus or rheumatoid arthritis can. However, having one autoimmune disease does increase the likelihood of developing others, which is why doctors often screen ITP patients for related conditions.
The autoimmune nature of ITP also explains why it can wax and wane unpredictably. Periods of remission may alternate with flares, and triggers like infections or stress can temporarily worsen platelet counts. For many people, ITP becomes a chronic but manageable condition once the right treatment approach is found.